Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

1. Evaluate the therapeutic effects, health benefits, and immunological effect of Al-hijamah in children with beta thalassemia major.

2. Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, in those patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Deferasirox

Criteria

Inclusion Criteria:

• Children suffering from beta thalassemia major, with age range from 4-18 years.

Exclusion Criteria:

• Children with Congenital heart disease

• Children with Rheumatic heart disease

• Presence of heart failure

• Children with Coronary arterial disease

• Children with Cardiomyopathy

• Children with hypotension

• Children with inflammatory skin diseases e.g. acute burns